Business context and reporting period
NorthView Acquisition Corp. filed this Form 10-Q for the quarter ended March 31, 2024; it was signed on October 9, 2024. NorthView is a shell company seeking to merge with Profusa, Inc. The filing is NorthView’s, not an operating-company financial report for Profusa. NorthView had not begun operations or generated operating revenue.
Financial results and position
| Metric | Q1 2024 / March 31, 2024 | Prior comparable period / December 31, 2023 |
|---|---|---|
| Revenue | None | None |
| Formation and operating costs | $470,841 | $443,717 in Q1 2023 |
| Net income (loss) | $(820,277) | $440,895 in Q1 2023 |
| Trust-account interest income | $116,664 | $1,845,005 in Q1 2023 |
| Warrant fair-value change | $(504,723) expense | $(574,137) expense in Q1 2023 |
| Cash and marketable securities in trust | $8,433,168 | $10,873,406 |
| Cash outside trust | $5,314 | $4,519 |
| Working-capital deficit | $3,898,430 | Not stated as a comparable figure |
| Convertible sponsor note | $1.5 million principal; $1,262,226 fair value | $944,118 fair value |
| Operating cash flow | $(280,853) | $(966,607) in Q1 2023 |
There are no meaningful revenue or operating margins to assess. Total liabilities were $4,625,856, including $614,287 of accounts payable and accrued expenses, $1,874,990 of excise tax payable, and $661,362 of warrant liabilities. NorthView reported no long-term debt or lease obligations.
Changes versus the prior comparable period
- NorthView moved from net income of $440,895 to a net loss of $820,277. Trust interest income fell substantially, while a $504,723 warrant remeasurement expense and operating costs contributed to the loss; a $60,077 gain from the convertible note’s fair-value change partly offset these items.
- Trust assets declined by approximately $2.44 million from year-end, principally reflecting redemptions and related transactions. Q1 operating cash use improved from the prior-year quarter.
- Public shares subject to possible redemption declined from 833,469 at year-end to 738,075 at March 31. The filing describes 95,394 redemptions approved at the March meeting and paid on March 26.
Transaction, outlook, risks and unusual items
- The proposed Profusa merger is subject to customary conditions, including at least $15 million of available cash, government approvals, and both companies’ stockholder approvals. The filing says completion is uncertain. The merger consideration is based on a $155 million pre-transaction equity value; Profusa stockholders may also receive up to 3,875,000 earnout shares subject to milestones.
- After quarter-end, the parties extended NorthView’s business-combination deadline to March 22, 2025. The filing states that NorthView may need monthly trust contributions to maintain extensions.
- A proposed $5 million Vellar investment was intended to fund at closing. Vellar terminated its term sheet on September 25, 2024; related fees were reported as $59,867, subject to payment by NorthView or Profusa. The filing does not establish replacement funding.
- Management reported substantial doubt about NorthView’s ability to continue as a going concern if it cannot complete a business combination by the deadline. With only $5,314 outside the trust and a working-capital deficit, NorthView relies on sponsor financing; sponsor advances are not guaranteed.
- NorthView recorded $1,874,990 of excise tax payable related to redemptions. The sponsor note is non-interest-bearing and may, at the sponsor’s election, be converted into shares at $2.22 per share; the filing also describes a possible warrant-conversion feature.
- Nasdaq had notified NorthView of a public-float market-value deficiency and late-reporting deficiencies. A filing exception required the Q1 and Q2 2024 reports by October 14, 2024; failure to comply could lead to delisting. The annual-meeting deficiency was subsequently resolved.
- Management concluded disclosure controls were ineffective as of March 31, 2024, citing a material weakness involving insurance expense, income taxes, and fair-value accounting for the convertible note. The filing was signed months after quarter-end.
No operating forecast or revenue guidance for NorthView is provided. Profusa-related earnout provisions are transaction terms, not management guidance.
Important facts for investors to verify
- Whether the Profusa merger can meet its $15 million minimum available-cash condition after Vellar’s termination, and what replacement financing is committed.
- The amount and accessibility of trust funds at the current date, subsequent redemptions and extension contributions, and the timeline to complete the merger.
- NorthView’s current Nasdaq listing and filing-compliance status, including resolution of the late-filing and public-float deficiencies.
- The status of the reported control material weakness and whether subsequent filings corrected the identified accounting and reporting issues.
- The sponsor note’s outstanding balance, conversion election and dilution implications, as well as the excise-tax liability and any further redemption-related obligations.